Evidence map›Paper›PMID 26138657›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2016

Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.

Jae Hyung Lee, Won Ki Lee

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Age-related differences in the prevalence of subtypes of Neovascular age-related macular degeneration in the first diagnosed eye.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019
    Observational
  2. Observational
  3. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2016
    Observational
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jae Hyung LeeDepartment of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, Republic of Korea.
Won Ki LeeDepartment of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, Republic of Korea. wklee@catholic.ac.kr.
Catholic University of Korea · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe objective of this study was to investigate the 2-year outcomes of treatment with anti-vascular endothelial growth factor (VEGF) in patients with polypoidal choroidal vasculopathy (PCV) with polyps resembling grape clusters.

methodsTwenty eyes in 20 patients were included. All patients initially received three consecutive anti-VEGF injections, followed by an as-needed re-injection schedule. Patients were followed regularly at 1- to 3-month intervals. The primary outcome was change in best-corrected visual acuity (BCVA).

resultsThe mean number of injections administered over the course of 24 months was 12.50 ± 2.77 (range, 9-18). The logarithm of the minimum angle of resolution (logMAR) BCVA improved from 0.61 ± 0.28 to 0.42 ± 0.27 at 12 months (P = 0.015), and 0.44 ± 0.31 at 24 months (P = 0.056). At 24 months, BCVA had improved in 6 (30.0 %) eyes by 0.3 logMAR or more, was stable in 11 (55.0 %) eyes, and had decreased in 3 (15.0 %) eyes. Complete absorption of fluid was achieved with anti-VEGF treatment in 18 (90 %) eyes at least once during the 2-year follow-up period, and 10 (50 %) eyes revealed a dry macula at 24 months. Two eyes (10.0 %) received rescue photodynamic therapy because subfoveal fluid persisted despite six and seven consecutive anti-VEGF injections. Of 18 eyes treated only with anti-VEGF agents, 3 (16.7 %) revealed partial resolution of the polypoidal lesions at 24 months.

conclusionsA treatment regimen with anti-VEGF effectively improved or maintained visual acuity over a 24-month period in patients with PCV with clusters of grape-like polyps, and required frequent injections, comparable to typical choroidal neovascularization in age-related macular degeneration.

Indexed as

AgedAged, 80 and overAngiogenesis InhibitorsChoroidal NeovascularizationFemaleFluorescein AngiographyFollow-Up StudiesHumansIntravitreal InjectionsMaleMiddle AgedPhotochemotherapyPolypsRanibizumabSubretinal FluidTomography, Optical CoherenceAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AVEGFA protein, humanAnti-vascular endothelial growth factorPhotodynamic therapyPolypoidal choroidal vasculopathy

Identifiers

PMID26138657
OpenAlexW846615141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.